Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency

Journal of Opioid Management

Volumn 7, Issue 5, 2011, Pages 371-376

  Oviedo Joekes, Eugenia ^a,b   Marsh, David C ^c   Guh, Daphne ^b   Brissette, Suzanne ^d   Schechter, Martin T ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Diacetylmorphine; Equipotency; Hydromorphone; Opioid dependency; Substitution treatment with opioid agonists

Indexed keywords

DIAMORPHINE; HYDROMORPHONE; METHADONE;

ARTICLE; CANADA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE CALCULATION; DRUG POTENCY; DRUG SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; OPIATE ADDICTION; PHASE 3 CLINICAL TRIAL (TOPIC); POTENCY RATIO; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ANALGESICS, OPIOID; CANADA; DOUBLE-BLIND METHOD; HEROIN; HUMANS; HYDROMORPHONE; INJECTIONS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 81855203280     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0078     Document Type: Article

References (23)

1. Cherny NI: Opioid analgesics: Comparative features and prescribing guidelines. Drugs. 1996; 51: 713-737.
2. Haasen C, van den Brink W: Innovations in agonist maintenance treatment of opioid-dependent patients. Curr Opin Psychiatry. 2006; 19: 631-636. (Pubitemid 44520380)
3. Anderson R, Saiers JH, Abram S, et al.: Accuracy in equianalgesic dosing. Conversion dilemmas. J Pain Symptom Manage. 2001; 21: 397-406. (Pubitemid 32452140)
4. Pereira J, Lawlor P, Vigano A, et al.: Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001; 22: 672-687. (Pubitemid 32725810)
5. Hill JL, Zacny JP: Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl). 2000; 152: 31-39.
6. Shaheen PE, Walsh D, Lasheen W, et al.: Opioid equianalgesic tables: Are they all equally dangerous? J Pa in Symptom Manage. 2009; 38: 409-417.
7. Seidenberg A, Honegger U: Metadona, hero 'na y otros Opioides: Manual para un tratamiento ambulatorio de mantenimiento con Opioides. Granada: Ediciones de D'az de Santos, 2000.
8. Patanwala AE, Duby J, Waters D, et al.: Opioid conversions in acute care. Ann Pharmacother. 2007; 41: 255-266.
9. Haemmig RB, Tschacher W: Effects of high-dose heroin versus morphine in intravenous drug users: A randomised double-blind crossover study. J Psychoactive Drugs. 2001; 33: 105-110. (Pubitemid 32643292)
10. Oviedo-Joekes E, Brissette S, Marsh DC, et al.: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009; 361: 777-786.
11. Oviedo-Joekes E, Guh D, Brissette S, et al.: Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: A pilot study. J Subst Abuse Treat. 2010; 38: 408-411.
12. Greenwald MK, Hursh SR: Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply. Drug Alcohol Depend. 2006; 85: 35-48. (Pubitemid 44310833)
13. Strain EC, Walsh SL, Bigelow GE: Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl). 2002; 159: 161-166. (Pubitemid 34146559)
14. Preston KL, Bigelow GE: Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther. 2000; 295: 114-124.
15. Wallenstein SL, Houde RW, Portenoy R, et al.: Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain. 1990; 41: 5-13. (Pubitemid 20152742)
16. Oviedo-Joekes E, Nosyk B, Marsh D, et al.: Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study. Clin Trials. 2009; 6: 261-271.
17. Oviedo-Joekes E, Nosyk B, Brissette S, et al.: The North American Opiate Medication Initiative (NAOMI): Profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health. 2008; 85: 812-825.
18. Dunbar PJ, Chapman CR, Buckley FP, et al.: Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain. 1996; 68: 265-270. (Pubitemid 27025883)
19. Mahler DL, Forrest WH Jr: Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology. 1975; 42: 602-607.
20. Jasinski DR, Preston KL: Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend. 1986; 17: 301-310. (Pubitemid 16060772)
21. Martin WR, Fraser HF: A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther. 1961; 133: 388-399.
22. McNicol E: Opioid equianalgesic conversions. J Pain Palliat Care Pharmacother. 2009; 23: 458; author reply 459.
23. Brands B, Marsh D, Busto U, et al.: Comparison of heroin and hydromorphone in opioid users. Clin Pharmacol Ther. 2004; 75: P3.